Abstract
Flexor tendon injuries heal with excessive scar tissue that limits range of motion and increases incidence of re-rupture. The molecular mechanisms that govern tendon healing are not well defined. Both the canonical nuclear factor kappa B (NF-κB) and mitogen activated protein kinase (MAPK) pathways have been implicated in tendon healing. The gene NFKB1 (proteins p105/p50) is involved in both NF-κB and MAPK signaling cascades. In the present study, we tested the hypothesis that global NFKB1 deletion would increase activation of both NF-κB and MAPK through loss of signaling repressors, resulting in increased matrix deposition and altered biomechanical properties. As hypothesized, NFKB1 deletion increased activation of both NF-κB and MAPK signaling. While gliding function was not affected, NFKB1 deletion resulted in tendons that were significantly stiffer and trending towards increased strength by four weeks post-repair. NFKB1 deletion resulted in increased collagen deposition, increase macrophage recruitment, and increased presence of myofibroblasts. Furthermore, NFKB1 deletion increased expression of matrix-related genes (Col1a1, Col3a1), macrophage-associated genes (Adgre1, Ccl2), myofibroblast markers (Acta2), and general inflammation (Tnf). Taken together, these data suggest that increased activation of NF-κB and MAPK via NFKB1 deletion enhance macrophage and myofibroblast content at the repair, driving increased collagen deposition and biomechanical properties.
Subject terms: Cell biology, Molecular biology
Introduction
Tendons are a dense connective tissue primarily composed of type I collagen. The collagen fibrils are organized into a hierarchical structure that confers strength and enables the tendon to transmit forces from muscle to bone. Following an acute tendon injury, large quantities of disorganized type III collagen-rich scar tissue are transiently deposited at the injury site. The healing process proceeds through inflammation, extracellular matrix deposition, and incomplete remodeling of scar tissue, leading to long-term deficits in tendon function and strength. It is postulated that the initial inflammatory stage of tendon healing drives scar tissue deposition. For example, fetal tendons heal in a regenerative manner following injury and are characterized by minimal inflammation1,2. In contrast adult tendons heal via deposition of scar tissue and experience a robust inflammatory phase characterized by an influx of inflammatory cells3. However, there is insufficient understanding of the pro-inflammatory signaling pathways that are activated following acute tendon injury, including how these pathways may modulate scar formation during healing.
Canonical nuclear factor kappa B (NF-κB) signaling is a pro-inflammatory signaling pathway that regulates hundreds of different genes including pro-inflammatory cytokines, chemokines, adhesion molecules, and enzymes through the heterodimer p65-p504. Canonical NF-κB signaling has been implicated in both chronic and acute tendon injuries5,6. Mitogen-activated protein kinase (MAPK) has also been implicated in scar-mediated tendon healing. MAPK signaling is a varied, multi-tiered signaling cascade with multiple effectors and downstream gene targets7,8. The extracellular signal-regulated protein kinases ERK1/2 is a well-characterized MAPK pathway that drives cell proliferation, differentiation, and expression of cell cycle proteins9. It has previously been shown that inhibition of ERK2 decreased tendon scar tissue formation following an acute flexor tendon injury and repair10.
The NFKB1 gene encodes the protein p105, which can undergo proteasomal processing to p5011. The protein p50 most commonly binds to p65 and together constitute the classic canonical NF-κB heterodimer that drives expression of pro-inflammatory genes. Both p65 and p50 have DNA binding domains; however, only p65 has a transactivation domain, preventing p50 from initiating gene expression. Additionally, it has been shown that p50 can bind to other p50 proteins to form p50 homodimers. The p50 homodimer can bind to DNA, but is unable to initiate gene transcription, therefore acting as a transcriptional repressor. Protein p105 binds to the kinase TPL2, preventing downstream phosphorylation of ERK1/2. Thus, deletion of the NFKB1 gene results in a complete absence of repressive p50 homodimers, and an uninhibited TPL2 kinase, likely stimulating increased activation of both canonical NF-κB signaling and ERK1/2 signaling.
In the present study, we characterized tendon healing in NFKB1 wildtype (NFKB1WT), heterozygote (NFKB1Het), and knockout (NFKB1KO) mice, and tested the hypothesis that global NFKB1KO activates canonical NF-κB and ERK1/2 signaling pathways, resulting in increased scar tissue deposition. We assessed the differences in canonical NF-κB and ERK1/2 signaling activation between genotypes and analyzed tendon gliding function and biomechanics in both uninjured and repaired flexor tendons. In addition, evaluation of repaired tendons identified changes in the cellular environment, matrix deposition, and downstream gene targets of NF-κB and MAPK signaling, which may drive the mechanical phenotypes that were observed during healing. These data provide evidence that increased activation of canonical NF-κB and ERK1/2 signaling, likely resulting from loss of p50 repressors and freeing of the TPL2 kinase, synergistically result in increased extracellular matrix deposition at the injury site, potentially driven by an increased presence of macrophages and myofibroblasts.
Results
NFKB1KO does not alter baseline tendon gliding function or mechanical properties
Expression of p50 and p105 were substantially reduced in NFKB1Het mice, relative to NFKB1WT, while complete deletion of p50 and p105 were observed in NFKB1KO mice via western blot (Fig. 1A). To ensure that NFKB1KO did not impair baseline tendon function and mechanical properties, uninjured tendons were assessed. No changes in MTP flexion angle (Fig. 1B), gliding resistance (Fig. 1C), stiffness (Fig. 1D), or maximum load at failure (Fig. 1E) were detected between genotypes.
NFKB1 knockout animals exhibit increased activation of canonical NF-κB and MAP kinase signaling during tendon healing compared to WT
The NFKB1 gene is involved in both canonical NF-κB and MAP Kinase signaling pathways (Fig. 2A). To assess the differences in pathway activation between genotypes in uninjured and at days 3 and 14 post-repair, western blots were performed. Elevated levels of phospho-p65 (p-p65) and total p65 were detected in NFKB1Het uninjured tendon relative to NFKB1WT and NFKB1KO uninjured tendon (Fig. 2B). Additionally, uninjured NFKB1Het and NFKB1KO tendons exhibited increased levels of total ERK1/2 protein relative to NFKB1WT littermates (Fig. 2B). Increased presence of p-p65 and p-ERK1/2 protein was detected in NFKB1KO animals compared to NFKB1WT littermates at 3 days post-repair, indicative of increased NF-κB and MAP Kinase activation, respectively (Fig. 2C). NFKB1Het animals also exhibited increased p-ERK1/2 and a modest increase in p-p65 (Fig. 2C), suggesting increased NF-κB and ERK signaling in NFKB1Het relative to NFKB1WT. By 14 days post-repair, both NFKB1Het and NFKB1KO repairs continue to exhibit increased levels of p-p65 relative to NFKB1WT. However, NFKB1Het repairs exhibit more p-p65 than NFKB1KO animals, suggesting that NFKB1Het had the highest activation of NF-κB signaling by this time-point (Fig. 2D). At day 14 post-repair, there were no apparent differences in p-ERK1/2 between genotypes, which suggests NFKB1-independent activation of ERK1/2 signaling at this time point (Fig. 2D). Thus, higher activation of canonical NF-κB signaling was seen in both NFKB1Het and NFKB1KO tendons relative to NFKB1WT at both days 3 and 14, while ERK1/2 signaling was more highly activated in these groups at day 3 alone.
NFKB1KO does not impair gliding function but delays restoration of mechanical properties of healing tendons
NFKB1KO healing tendons did not differ significantly in MTP flexion angle (Fig. 3A) or gliding resistance (Fig. 3B) compared to NFKB1Het and NFKB1WT littermates at either 14- or 28-days post-repair (Normalized to uninjured data in figure 1– MTP flexion angle: WTD14: 27.3%, WTD28: 58.9%, HetD14: 35.9%, HetD28: 53.6%, KOD14: 26.0%, KOD28: 55.5%) (Normalized to uninjured data in figure 1– Gliding Resistance: WTD14: 1225.4%, WTD28: 235.3%, HetD14: 521.4%, HetD28: 277.6%, KOD14: 1580.6%, KOD28: 284.8%). While the stiffness did not significantly differ between genotypes at 14 days post-repair, NFKB1KO tendons were significantly stiffer than NFKB1WT tendons (WT: 3.62N/mm ± 0.39, KO: 6.20N/mm ± 0.94, p = 0.0359) at 28 days post-repair, with no significant difference compared to NFKB1Het tendon (KO vs Het, p = 0.4572) (Fig. 3C) (Normalized to uninjured data in figure 1– Stiffness: WTD14: 13.0%, WTD28: 10.8%, HetD14: 11.9%, HetD28: 15.6%, KOD14: 11.4%, KOD28: 22.1%). NFKB1KO tendon maximum load at failure was significantly decreased compared to NFKB1Het mice (Het: 0.826N ± 0.06, KO: 0.562N ± 0.06, p = 0.0210), but not NFKB1WT mice (WT: 0.744N ± 0.06, p = 0.1392 vs. KO) at day 14 (Fig. 3D). While the differences in maximum load at failure were not statistically significant at day 28, NFKB1KO tendons were trending towards improved strength relative to NFKB1WT animals (KO vs WT, p = 0.0829) with no differences compared to NFKB1Het mice (KO vs Het, p = 0.9387) (Normalized to uninjured data in figure 1– Maximum Load at Failure: WTD14: 8.0%, WTD28: 15.2%, HetD14: 11.1%, HetD28: 26.4%, KOD14: 7.0%, KOD28: 26.1%). Between days 14 and 28, wildtype tendon maximum load at failure improved by 84% and NFKB1KO tendons improved by 272%, indicating accelerated healing for the NFKB1KO repairs.
NFKB1KO tendons exhibit increased collagen deposition at the repair site
Visualization with ABHOG and Masson’s Trichrome stains exhibited no differences between genotypes in uninjured tendons (Fig. 4A,B). Histologically, there were no apparent differences in scar tissue morphology between genotypes (Fig. 4C). However, NFKB1Het and NFKB1KO had increased blood vessel presence in the scar tissue compared to NFKB1WT mice, possibly indicative of increased angiogenesis. Masson’s trichrome demonstrated that NFKB1KO and NFKB1Het mice had increased collagen deposition at the repair site relative to NFKB1WT littermates (Fig. 4D).
Increased presence of αSMA+ Myofibroblasts and F4/80+ macrophages at NFKB1Het and NFKB1KO repair sites
As it has previously been shown that both macrophages and myofibroblasts contribute to increased matrix deposition and are present during normal flexor tendon healing12,13, we used immunohistochemistry to assess their contribution to alterations in biomechanical phenotypes and collagen content seen in NFKB1Het and NFKB1KO mice. Uninjured tendons contained no F4/80+ or αSMA+ cells, or exhibited changes in S100a4+ cell content, between genotypes (Fig. 5A–C). We observed an increased presence of F4/80+ macrophages and α-SMA+ myofibroblasts in NFKB1Het and NFKB1KO mice relative to NFKB1WT mice at 14 days post-repair (Fig. 5D,E). We have previously shown that S100a4+ cells are present within the tendon and throughout the scar tissue during healing, contributing to the formation of scar13,14. There were no observable differences in the S100a4+ population between genotypes 14 days post-repair (Fig. 5F).
Screening for differential gene expression in NFKB1KO animals compared to wildtypes
To screen for potential gene targets between genetic groups 14 days post-repair, a custom-designed PCR array plate was utilized (Supplemental Fig. S1). Six genes were found to be upregulated in NFKB1KO tendon relative to NFKB1WT (Col1a1, Adgre1 (F4/80), Ccl2, Acta2 (α-SMA), Tnf, Col3a1) (Fig. 6, red color). Five genes were upregulated in NFKB1Het relative to NFKB1WT (Col1a1, Adgre1, Col3a1, S100a4, Hif1a) (Fig. 6, red color). Furthermore, five genes were differentially expressed in NFKB1Het compared to NFKB1KO (Ccl2, Acta2, Tnf, S100a4, Hif1a) (Fig. 6). Thus, NFKB1Het and NFKB1KO exhibit divergent gene expression patterns by day 14 post-repair, and both exhibit gene expression patterns different from NFKB1WT.
Discussion
In the present study, we assessed the effects of global NFKB1KO on flexor tendon healing. We established that loss of NFKB1 resulted in increased activation of canonical NF-κB and early activation of ERK1/2 signaling following injury, relative to WT littermates. While NFKB1KO did not affect baseline tendon gliding function or biomechanical properties, loss of NFKB1 altered tendon strength during healing. NFKB1KO mice exhibited increased collagen deposition, in addition to increased macrophage and myofibroblast presence. Interestingly, while no statistically significant differences in mechanical properties were observed between NFKB1WT and NFKB1KO repairs at 14 days post-repair, the maximum load at failure was reduced in NFKB1KO relative to NFKB1HET at D14. Consistent with this, complete knockout of p65 in mice contributed to osteoarthritis (OA) development while p65 haploinsufficient animals were protective against OA, suggesting that haploinsufficiency of canonical NF-κB genes can be beneficial in certain pathologies15. Thus, loss of one copy of the NFKB1 gene may be beneficial during early tendon healing, explaining why significant differences were detected between NFKB1KO and NFKB1Het animals. Furthermore, gene analysis at day 14 post-repair suggested different expression profiles in NFKB1Het and NFKB1KO animals, which could also explain the differences in day 14 biomechanics at this time point. By 28 days post-repair NFKB1KO were no longer significantly different than NFKB1Het littermates and were trending towards increased strength relative to NFKB1WT littermates. In addition, NFKB1KO tendons were significantly stiffer than NFKB1WT tendons at 28 days post-repair, suggesting that NFKB1KO tendons heal more robustly in later stages of healing compared to NFKB1WT, perhaps suggesting an accelerated healing process. Previous studies that associate NFKB1 with improved biomechanical properties are limited; however, downregulation of NFKB1 gene expression is associated with osteoporotic bone16,17, and NFKB1KO mice are resistant to bone loss related to mechanical unloading18, suggesting that NFKB1 is necessary for the maintenance of musculoskeletal tissue.
The increase in collagen deposition at the injury site in NFKB1Het and NFKB1KO repairs relative to NFKB1WT at 14 days post-repair is consistent with the increased gene expression of collagens type I and type III, which were also observed in these genotypes. This increase in collagen deposition may in turn contribute to the robust increase in maximum load from 14 to 28 days post-repair in NFKB1KO repairs. These observations are consistent with increased matrix deposition during skin inflammation and chronic liver injury in NFKB1KO mice19,20. Moreover, several of the cell types present during tendon healing can contribute to collagen-rich scar tissue formation, including fibroblasts, myofibroblasts, and macrophages. Thus, it is possible that NFKB1KO may drive excessive scar tissue deposition via changes in recruitment, proliferation, or activation of one or more of these cell types.
Phosphorylation, and therefore activation, of p65 is an accepted marker of canonical NF-κB signaling. NF-κB can drive expression of hundreds of genes, including genes that can continue to re-activate canonical NF-κB signaling (IL-1β and TNF-α) as well as genes that aid in shutting down the pathway (IκBα and p50/p105). Deletion of p50/p105 results in loss of one of the ways canonical NF-κB mediates its own shut-down, resulting in continued, and likely elevated, activation of canonical NF-κB signaling. Thus, deletion of p50/p105 can result in increased canonical NF-κB, and thus increased presence of p-p65. The effects of NFKB1KO on both canonical NF-κB signaling and ERK1/2 signaling are cell- and tissue-type dependent. For example, Han et al., demonstrate increased NF-κB activation in non-hematopoietic cells and bone marrow derived macrophages of NFKB1KO mice21, while Frantz et al. identified decreased NF-κB activation in NFKB1KO spleen lymphocytes22. Here we show that NFKB1KO increased phosphorylation of p65 during healing, relative to NFKB1WT, indicating that loss of NFKB1 results in enhanced activation of canonical NF-κB signaling during tendon healing. Moreover, it is well established that p105 inhibits TPL2 kinase activity, reducing phosphorylation of ERK1/211, and we demonstrate increased early phosphorylation of ERK1/2 at D3 in NFKB1KO, relative to NFKB1WT. In contrast, Fearn et al., demonstrated that NFKB1KO prevented ERK1/2 phosphorylation in bone marrow derived macrophages23, further exhibiting the cell type-specific effects of NFKB1KO. In the present study, we found overall increases in canonical NF-κB and early ERK1/2 activation of cells involved in tendon healing, which we hypothesize to be due to the loss of repressive p50 homodimers and uninhibited TPL2 kinase. However, we did not examine the activation of these pathways in specific cell types present at the injury site. Future studies focused on delineating the cell specific contributions of canonical NF-κB and ERK1/2 signaling activation on tendon healing are needed.
NF-κB mediated expression of macrophage-specific chemokines enhances recruitment of macrophages to the healing tissue24. Macrophages play many important and diverse roles during healing25, and macrophage depletion during tendon healing decreases scar tissue26,27. In our study, NFKB1KO and NFKB1Het mice exhibit increased F4/80+ macrophages presence at the injury site compared to NFKB1WT animals. This is further supported by the increased expression of Adgre1 (F4/80) and CCL2 (macrophage chemokine) in NFKB1Het and NFKB1KO repairs. Macrophages can induce fibroblasts to differentiate into myofibroblasts, a population characterized by extracellular matrix deposition and an ability to contract, which aids in wound closure28. We found that αSMA+ myofibroblasts cell number appeared elevated in NFKB1KO and NFKB1Het mice at the repair sites compared to NFKB1WT animals, which corresponds to higher expression levels of ACTA2 in NFKB1KO tendons. This is consistent with previous studies that showed NFKB1KO animals exhibited elevated scar tissue deposition accompanied by increased αSMA+ myofibroblasts following chronic liver injury19,20. Future studies will be needed to elucidate whether the elevated number of αSMA+ myofibroblasts was due to increased recruitment of circulating fibrocytes, increased proliferation of fibroblasts at the repair site that were later induced to differentiate, or an increase in the rate of myofibroblast differentiation. As there are no changes in S100a4+ cells, which are a predominately fibroblastic cell population, the increase in αSMA+ myofibroblast presence seen in NFKB1KO repairs is likely due to increased differentiation rather than an overall increase in fibroblast cell number. NFKB1KO may modulate the macrophage-myofibroblast axis during healing, resulting in the elevated presence of these populations that could influence the matrix deposition and therefore biomechanical properties of the healing tendon. However, further studies are necessary to delineate the precise effects of each cell type on one another. Altogether, the elevated scar tissue deposition seen in the NFKB1KO mice is associated with the increased presence of F4/80+ macrophages and αSMA+ myofibroblasts.
Both canonical NF-κB and MAPK signaling contribute to angiogenesis. NF-κB signaling can drive expression of vascular endothelial growth factor (VEGF), which promotes vessel formation29, but NF-κB can also drive expression of vascular endothelial grown inhibitor (VEGI), which inhibits angiogenesis30. ERK signaling can promote both expression and transcriptional activation of HIF-1α, another factor that drives angiogenesis31. NFKB1Het and NFKB1KO mice exhibited increased vessel formation relative to NFKB1WT animals (Figs 4C and 5E). NFKB1Het tendons also had increased levels of HIF1A relative to NFKB1WT. Increased vascularity likely improves delivery of circulating cells, including monocytes and fibrocytes, to the healing tendon. Monocytes and fibrocytes can differentiate into macrophages and myofibroblasts, respectively, which could explain the increased presence of these cell types in the NFKB1Het and NFKB1KO mice. Macrophages have been shown to release VEGF to stimulate vessel formation, suggesting that an elevated macrophage presence due to increased NF-κB activation could be driving the development of vessel formation25.
One limitation of this study is that NFKB1KO is a global knockout of NFKB1 in all cell types. Therefore, it cannot be conclusively stated which cell types specifically contributed to the altered tendon biomechanics, collagen deposition, cell diversity, and gene expression. Further studies are needed to accurately assess how activated NF-κB and ERK1/2 signaling affected the various cell types present at the healing tendon.
Altogether, these data demonstrate that canonical NF-κB and ERK1/2 signaling cascades contribute to tendon healing. Global activation of these pathways resulted in tendon repairs that heal with improved biomechanics relative to wildtype controls. Analysis of NFKB1KO repairs suggests this improvement in biomechanics is associated with increased collagen deposition, possibly due to increased macrophage and myofibroblast content at the repair. This study provides further evidence that canonical NF-κB signaling is involved in tendon healing and provides rationale to interrogate the specific NF-κB dependent roles of various cell types during healing, such as tendon cells, macrophages, and myofibroblasts. Understanding the effects of various signaling cascades on tendon healing will help inform on future therapeutic strategies with the goal of minimizing scar tissue formation while improving tendon mechanical properties. Ultimately, directly targeting NF-κB signaling as a method for improving tendon healing in patients would likely be detrimental as canonical NF-κB signaling can influence expression of hundreds of different genes, many of which are important for homeostasis. However, better understanding the downstream processes mediated by NF-κB signaling could reveal candidate pathways that could be viably targeted by therapeutics.
Methods
Animal ethics
This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. All animal procedures were approved by the University Committee on Animal Research (UCAR) at the University of Rochester.
Mice
NFKB1KO mice were obtained from Jackson Laboratory (#002849, Bar Harbor, ME). NFKB1KO 32 mice were generated by disrupting exon 6 of the NFKB1 gene, resulting in loss of NFKB1 gene expression and the gene products p105 and p50. Animals were maintained as heterozygotes, resulting in litters consisting of wildtype (NFKB1WT), heterozygote (NFKB1Het), and knockout (NFKB1KO) pups. Animals were group-housed with up to five animals per cage in pathogen-free housing with ad libitum access to food and water. All mouse studies were performed with 10–12 week-old male and female mice.
Flexor tendon repair
To mimic acute tendon injuries repaired in the clinic, mice underwent complete transection and repair of the flexor digitorum longus (FDL) tendon in the right hindpaw as previously described33. Briefly, mice were injected prior to surgery with 15–20 μg of sustained-release buprenorphine. Mice were then anesthetized with Ketamine (60 mg/kg) and Xylazine (4 mg/kg). Following preparation of the surgical site, the FDL was transected at the myotendinous junction in the calf to protect the repair site from rupture due to transmitted force. The skin was closed with a 5–0 suture. A small incision was made to the posterior surface of the hindpaw. The soft tissue was retracted and the FDL isolated using forceps, and the FDL was completely transected using micro-scissors. Following FDL transection, the tendon was repaired using 8-0 sutures and the skin closed with 5-0 sutures. Following repair surgery, the animals were unrestricted in movement, food intake, and water consumption.
Protein extraction and western blot
Total protein was extracted from NFKB1 mouse tendons uninjured and at days 3 and 14 post-repair. Samples were collected at the repair site and 1–2 mm of native tendon on either side of the repair, with three tendons pooled per genotype per timepoint. Thus, the protein contribution is reflective of both tendon and the surrounding scar tissue. Tendons were homogenized using 0.5 mm zirconium oxide beads and a Bullet Blender Gold Cell Disrupter (Next Advance Inc., Troy, NY), protein was extracted using radioimmunoprecipitation assay buffer (RIPA) buffer with added protease/phosphatase inhibitors, and 20 µg were loaded into each well of a NuPAGE 4–12% Bis-Tris Gel (Invitrogen, Carlsbad, CA). Following transfer, membranes were probed with antibodies for phospho-p65 (1:1000, Cat#: 3033, Cell Signaling, Danvers, MA), total p65 (1:1000, Cat#: 8242, Cell Signaling, Danvers, MA), phospho-ERK1/2 (1:1000, Cat#: 4377, Cell Signaling, Danvers, MA), total ERK1/2 (1:1000, Cat#: 9102, Cell Signaling, Danvers, MA), p105/p50 (1:1000, Cat#: 13586, Cell Signaling, Danvers, MA), and GAPDH (1:1000, Cat#: 2118, Cell Signaling, Danvers, MA).
RNA extraction and gene array analysis
Total RNA was extracted from healing tendons at 14 days post-repair. RNA was collected from the repair site and 1–2 mm of native tendon on either side of the repair, with three tendons pooled per genotype. RNA was extracted using Trizol reagent (Life Technologies, Carlsbad, CA). 2000 ng of RNA was used for reverse transcription of cDNA using iScript cDNA synthesis kit (Biorad, Cat#:1708890, Hercules, CA). 10 ng of cDNA along with iTaq Universal SYBR Green Supermix (Biorad, Cat#:1725120, Hercules, CA) were added to each well of a custom PCR array plate (Biorad, Hercules, CA) (Supplemental Fig. 1). Data analysis was performed using Biorad CFX Manager 3.1 software (Biorad, Hercules, CA). Of the three housekeeping genes analyzed, 40S ribosomal protein S18 (RSP18) was used as the internal reference gene as it was the most consistent between genotypes. Data is presented as a Clustergram, where red tiles represent high gene expression and blue tiles represent low gene expression.
Histology and Immunofluorescence
Hindpaws were harvested uninjured and at day 14 post-repair (n = 4–5 per genotype). Hindpaws were fixed in 10% neutral buffered formalin (NBF) at room temperature for 72 hours, decalcified in 14% EDTA (pH 7.2–7.4) for 2 weeks at room temperature, processed, and embedded in paraffin. Three-micron sagittal sections were cut, de-waxed, and dehydrated for analysis. Sections were stained with Alcian blue/hematoxylin and Orange G (ABHOG) for tissue morphology, and Masson’s Trichrome for collagen content. For immunofluorescence, sections were probed with antibodies for α-SMA-CY3 (1:200, Cat#: C6198, Sigma Life Sciences, St. Louis, MO), F4/80 (1:500, Cat#: sc-26643, Santa Cruz, Dallas, TX), and S100a4 (1:2000, Cat#: ab197896, Abcam, Cambridge, MA) overnight at 4 °C. A Rhodamine Red-X AffiniPure secondary antibody was used with F4/80 and S100a4 (1:200, Cat#: 711–296–152, Jackson ImmunoResearch, West Grove, PA). Sections were then counterstained with the nuclear stain DAPI and imaged using a VS120 Virtual Slide Microscope (Olympus, Waltham, MA).
Assessment of gliding function and biomechanical properties
Tendon gliding function was assessed as previously described34. Briefly, hindlimbs were harvested at the knee-joint and the proximal end of the FDL tendon was detached at the myotendinous junction. The FDL tendon was secured between two pieces of tape with cyanoacrylate and the hindlimb was held in an alligator clip. The FDL tendon was loaded incrementally with small weights from 0 to 19 g with images captured after each load. Measurement of the flexion angle of the metatarsophalangeal (MTP) joint relative to the unloaded position were made using Image J. Gliding resistance was derived from the changes in MTP flexion angle over the range of applied loads. An increase in Gliding Resistance and reduction in MTP Flexion Angle is associated restricted range of motion and increased scar tissue. Following gliding testing, the FDL tendon was released from the tarsal tunnel. The proximal end of the tendon and the toes of the hindpaw were help in place by opposing clamps on an Instron 8841 uniaxial testing system (Instron Corporation, Norwood, MA). The tendon was loaded until failure at a rate of 30 mm/minute34,35. Nine-15 samples per genotype per time point were analyzed.
Statistical analysis
Quantitative data was analyzed via GraphPad Prism and is presented as mean ± standard error of the mean (SEM). Normality was assessed using the D’Agostino & Pearson test. For normal datasets, a one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons test was used to analyze gliding and biomechanical data between genotypes at a given time point. For non-normal data (D14 gliding resistance and D14 stiffness), a Kruskal-Wallis test with Dunn’s multiple comparisons test was utilized.
Supplementary information
Acknowledgements
We would like to thank the Histology, Biochemistry and Molecular Imaging (HBMI) and the Biomechanics, Biomaterials and Multimodal Tissue Imaging (BBMTI) for technical assistance with the histology and biomechanical testing, respectively. This work was supported in part by NIH/ NIAMS R01AR056696 (to HAA), K01AR068386 and R01AR073169 (to AEL). The HBMI and BBMTI Cores were supported by NIH/ NIAMS P30AR069655. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Contributions
Study conception and design: K.T.B., A.E.L. Acquisition of data: K.T.B., F.K.L., E.K. Analysis and interpretation of data: K.T.B., H.A.A., A.E.L. Drafting of manuscript: K.T.B., A.E.L. Revision and approval of manuscript: K.T.B., F.K.L., E.K., H.A.A., A.E.L.
Data Availability
All data generated or analyzed during this study are included in this article.
Competing Interests
The authors declare no competing interests.
Footnotes
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Supplementary information accompanies this paper at 10.1038/s41598-019-47461-5.
References
- 1.Beredjiklian PK, et al. Regenerative versus reparative healing in tendon: a study of biomechanical and histological properties in fetal sheep. Annals of biomedical engineering. 2003;31:1143–1152. doi: 10.1114/1.1616931. [DOI] [PubMed] [Google Scholar]
- 2.Favata M, et al. Regenerative properties of fetal sheep tendon are not adversely affected by transplantation into an adult environment. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2006;24:2124–2132. doi: 10.1002/jor.20271. [DOI] [PubMed] [Google Scholar]
- 3.Manning CN, et al. The early inflammatory response after flexor tendon healing: a gene expression and histological analysis. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2014;32:645–652. doi: 10.1002/jor.22575. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Hayden MS, Ghosh S. NF-kappaB, the first quarter-century: remarkable progress and outstanding questions. Genes & development. 2012;26:203–234. doi: 10.1101/gad.183434.111. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Chen S, et al. RelA/p65 inhibition prevents tendon adhesion by modulating inflammation. cell proliferation, and apoptosis. Cell death & disease. 2017;8:e2710. doi: 10.1038/cddis.2017.135. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Abraham Adam C., Shah Shivam A., Golman Mikhail, Song Lee, Li Xiaoning, Kurtaliaj Iden, Akbar Moeed, Millar Neal L., Abu-Amer Yousef, Galatz Leesa M., Thomopoulos Stavros. Targeting the NF-κB signaling pathway in chronic tendon disease. Science Translational Medicine. 2019;11(481):eaav4319. doi: 10.1126/scitranslmed.aav4319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Keshet Y, Seger R. The MAP kinase signaling cascades: a system of hundreds of components regulates a diverse array of physiological functions. Methods in molecular biology (Clifton, N.J.) 2010;661:3–38. doi: 10.1007/978-1-60761-795-2_1. [DOI] [PubMed] [Google Scholar]
- 8.Morrison D. K. MAP Kinase Pathways. Cold Spring Harbor Perspectives in Biology. 2012;4(11):a011254–a011254. doi: 10.1101/cshperspect.a011254. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Roskoski R., Jr. ERK1/2 MAP kinases: structure, function, and regulation. Pharmacological research. 2012;66:105–143. doi: 10.1016/j.phrs.2012.04.005. [DOI] [PubMed] [Google Scholar]
- 10.Ruan H, Liu S, Li F, Li X, Fan C. Prevention of Tendon Adhesions by ERK2 Small Interfering RNAs. International journal of molecular sciences. 2013;14:4361–4371. doi: 10.3390/ijms14024361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Cartwright Tyrell, Perkins Neil D., L. Wilson Caroline. NFKB1: a suppressor of inflammation, ageing and cancer. The FEBS Journal. 2016;283(10):1812–1822. doi: 10.1111/febs.13627. [DOI] [PubMed] [Google Scholar]
- 12.Ackerman Jessica E., Geary Michael B., Orner Caitlin A., Bawany Fatima, Loiselle Alayna E. Obesity/Type II diabetes alters macrophage polarization resulting in a fibrotic tendon healing response. PLOS ONE. 2017;12(7):e0181127. doi: 10.1371/journal.pone.0181127. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ackerman, J. E., Best, K. T., O’Keefe, R. J. & Loiselle, A. E. Deletion of EP4 in S100a4-lineage cells reduces scar tissue formation during early but not later stages of tendon healing. Scientific reports7, 8658, 10.1038/s41598-017-09407-7 (2017). [DOI] [PMC free article] [PubMed]
- 14.Ackerman, J. E. et al. Cell non-autonomous functions of S100a4 drive fibrotic tendon healing. Elife, 8 (2019). [DOI] [PMC free article] [PubMed]
- 15.Kobayashi H, et al. Biphasic regulation of chondrocytes by Rela through induction of anti-apoptotic and catabolic target genes. Nature communications. 2016;7:13336. doi: 10.1038/ncomms13336. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Balla B, et al. Different gene expression patterns in the bone tissue of aging postmenopausal osteoporotic and non-osteoporotic women. Calcified tissue international. 2008;82:12–26. doi: 10.1007/s00223-007-9092-3. [DOI] [PubMed] [Google Scholar]
- 17.Balla B, et al. Transcriptional profiling of immune system-related genes in postmenopausal osteoporotic versus non-osteoporotic human bone tissue. Clinical immunology (Orlando, Fla.) 2009;131:354–359. doi: 10.1016/j.clim.2009.01.004. [DOI] [PubMed] [Google Scholar]
- 18.Nakamura H, et al. Disruption of NF-kappaB1 prevents bone loss caused by mechanical unloading. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2013;28:1457–1467. doi: 10.1002/jbmr.1866. [DOI] [PubMed] [Google Scholar]
- 19.Oakley F, et al. Nuclear factor-kappaB1 (p50) limits the inflammatory and fibrogenic responses to chronic injury. The American journal of pathology. 2005;166:695–708. doi: 10.1016/S0002-9440(10)62291-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Fullard N, et al. The c-Rel subunit of NF-kappaB regulates epidermal homeostasis and promotes skin fibrosis in mice. The American journal of pathology. 2013;182:2109–2120. doi: 10.1016/j.ajpath.2013.02.016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Han W, et al. Myeloid cells control termination of lung inflammation through the NF-kappaB pathway. American journal of physiology. Lung cellular and molecular physiology. 2009;296:L320–327. doi: 10.1152/ajplung.90485.2008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Frantz S, et al. Tissue-specific effects of the nuclear factor kappaB subunit p50 on myocardial ischemia-reperfusion injury. The American journal of pathology. 2007;171:507–512. doi: 10.2353/ajpath.2007.061042. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Fearn A, et al. The NF-kappaB1 is a key regulator of acute but not chronic renal injury. Cell death & disease. 2017;8:e2883. doi: 10.1038/cddis.2017.233. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Hoesel B, Schmid JA. The complexity of NF-kappaB signaling in inflammation and cancer. Molecular cancer. 2013;12:86. doi: 10.1186/1476-4598-12-86. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Wynn TA, Vannella KM. Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity. 2016;44:450–462. doi: 10.1016/j.immuni.2016.02.015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.de la Durantaye M, Piette AB, van Rooijen N, Frenette J. Macrophage depletion reduces cell proliferation and extracellular matrix accumulation but increases the ultimate tensile strength of injured Achilles tendons. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2014;32:279–285. doi: 10.1002/jor.22504. [DOI] [PubMed] [Google Scholar]
- 27.Hays PL, et al. The role of macrophages in early healing of a tendon graft in a bone tunnel. The Journal of bone and joint surgery. American volume. 2008;90:565–579. doi: 10.2106/jbjs.f.00531. [DOI] [PubMed] [Google Scholar]
- 28.Pakshir Pardis, Hinz Boris. The big five in fibrosis: Macrophages, myofibroblasts, matrix, mechanics, and miscommunication. Matrix Biology. 2018;68-69:81–93. doi: 10.1016/j.matbio.2018.01.019. [DOI] [PubMed] [Google Scholar]
- 29.Xie TX, Xia Z, Zhang N, Gong W, Huang S. Constitutive NF-kappaB activity regulates the expression of VEGF and IL-8 and tumor angiogenesis of human glioblastoma. Oncology reports. 2010;23:725–732. doi: 10.3892/or_00000813. [DOI] [PubMed] [Google Scholar]
- 30.Xiao Q, et al. Characterization of cis-regulatory elements of the vascular endothelial growth inhibitor gene promoter. The Biochemical journal. 2005;388:913–920. doi: 10.1042/bj20041739. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Masoud GN, Li W. HIF-1alpha pathway: role, regulation and intervention for cancer therapy. Acta pharmaceutica Sinica. B. 2015;5:378–389. doi: 10.1016/j.apsb.2015.05.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sha WC, Liou HC, Tuomanen EI, Baltimore D. Targeted disruption of the p50 subunit of NF-kappa B leads to multifocal defects in immune responses. Cell. 1995;80:321–330. doi: 10.1016/0092-8674(95)90415-8. [DOI] [PubMed] [Google Scholar]
- 33.Ackerman, J. E. & Loiselle, A. E. Murine Flexor Tendon Injury and Repair Surgery. Journal of visualized experiments: JoVE, 10.3791/54433 (2016). [DOI] [PMC free article] [PubMed]
- 34.Hasslund S, et al. Adhesions in a murine flexor tendon graft model: autograft versus allograft reconstruction. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2008;26:824–833. doi: 10.1002/jor.20531. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Loiselle AE, et al. Remodeling of murine intrasynovial tendon adhesions following injury: MMP and neotendon gene expression. Journal of orthopaedic research: official publication of the Orthopaedic Research Society. 2009;27:833–840. doi: 10.1002/jor.20769. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data generated or analyzed during this study are included in this article.